Compare Ascendis Pharma A/S (ASND) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs ING Groep NV — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while ING Groep NV trades at $35.49 (market cap $101.22B). The key difference: ING Groep NV is far larger — about 6.1× Ascendis Pharma A/S's market cap, and ING Groep NV pays a 3.73% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ING | |
|---|---|---|
Market Cap | $16.67B | $101.22B |
Sector | Health | Financials |
52-Week High | $277.18 | $35.92 |
52-Week Low | $189.74 | $23.66 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 3.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
